Related Experiment Video

Updated: Oct 27, 2025

Author Spotlight: Advancing the Analysis of Plasma Extracellular Vesicle Proteome for Cardiovascular Biomarker Studies
05:30

Author Spotlight: Advancing the Analysis of Plasma Extracellular Vesicle Proteome for Cardiovascular Biomarker Studies

Published on: January 31, 2025

731

Extracellular vesicles - mediating and delivering cardioprotection in acute myocardial infarction and heart failure

Aishwarya Prakash1, Gustavo E Crespo-Avilan1,2,3, Sauri Hernandez-Resendiz1,2,4

  • 1Cardiovascular and Metabolic Disorder Programme, Duke-NUS Medical School, Singapore.

Conditioning Medicine
|July 23, 2021
PubMed

Insights

Extracellular vesicles (EVs) are crucial for heart protection after myocardial infarction (MI). Stem cell-derived EVs show therapeutic potential for reducing infarct size and preventing heart failure in patients with acute myocardial infarction (AMI).

Area of Science:

  • Cardiovascular Biology
  • Regenerative Medicine
  • Extracellular Vesicle Biology

Background:

  • Acute myocardial infarction (AMI) necessitates treatments to limit infarct size and prevent adverse cardiac remodeling, thereby preserving function and averting heart failure.
  • Extracellular vesicles (EVs) are increasingly recognized as vital mediators of intercellular communication within the heart, contributing to homeostasis and innate cardioprotective mechanisms like remote ischemic conditioning.

Purpose of the Study:

  • To review the multifaceted roles of EVs in mediating and delivering cardioprotection following myocardial infarction.
  • To discuss the therapeutic potential and challenges of utilizing EVs, particularly stem cell-derived EVs, for clinical application in acute myocardial infarction patients.
  • To explore the use of EVs as drug delivery vehicles for synergistic cardioprotective strategies.

Main Methods:

  • Literature review synthesizing current research on extracellular vesicles in the context of myocardial infarction.
  • Analysis of studies investigating endogenous and stem cell-derived EVs for cardioprotective effects in preclinical models of AMI.
  • Examination of the potential of EVs as therapeutic agents and drug delivery platforms.

Main Results:

  • Endogenous EVs play significant roles in maintaining cardiac function and mediating innate cardioprotection.
  • Stem cell-derived EVs have demonstrated efficacy in reducing infarct size and improving cardiac function in various animal models of AMI.
  • EVs show promise as carriers for targeted drug delivery, potentially enhancing cardioprotective therapies.

Conclusions:

  • Extracellular vesicles represent a promising therapeutic avenue for managing acute myocardial infarction and its sequelae.
  • Further research and overcoming existing challenges are necessary to translate the therapeutic potential of EVs into clinical practice for AMI patients.
  • EVs offer a versatile platform for both direct cardioprotection and as sophisticated drug delivery systems.

Keywords:
Cardioprotectionacute myocardial infarctiondrug deliveryexosomesextracellular vesiclesheart failure

More Related Videos

Purification and Transplantation of Myogenic Progenitor Cell Derived Exosomes to Improve Cardiac Function in Duchenne Muscular Dystrophic Mice08:13

Purification and Transplantation of Myogenic Progenitor Cell Derived Exosomes to Improve Cardiac Function in Duchenne Muscular Dystrophic Mice

Published on: April 10, 2019

6.2K
Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model14:24

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

11.9K

Related Concept Videos

Overview of Exosomes01:36

Overview of Exosomes

Exosomes are stable, lipid bilayer-enclosed vesicles capable of crossing biological barriers. They can carry a wide range of molecules required for intercellular communication. Once exosomes are released from the cell where they originated, they enter a recipient cell through various pathways such as fusion, receptor-mediated endocytosis, macropinocytosis, and phagocytosis.
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
3.0K
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
91
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
114
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
448
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
74
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.0K